These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 8123843)
41. Molecular genetics of type 2 von Willebrand disease. Fressinaud E; Mazurier C; Meyer D Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298 [TBL] [Abstract][Full Text] [Related]
42. Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets. Nishio K; Fujimura Y; Niinomi K; Takahashi Y; Yoshioka A; Fukui H; Usami Y; Titani K; Ruggeri ZM; Zimmerman TS Am J Hematol; 1990 Apr; 33(4):261-6. PubMed ID: 2316510 [TBL] [Abstract][Full Text] [Related]
43. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Fricke WA; Brinkhous KM; Garris JB; Roberts HR Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998 [TBL] [Abstract][Full Text] [Related]
44. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037 [TBL] [Abstract][Full Text] [Related]
45. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Ribba AS; Loisel I; Lavergne JM; Juhan-Vague I; Obert B; Cherel G; Meyer D; Girma JP Thromb Haemost; 2001 Sep; 86(3):848-54. PubMed ID: 11583318 [TBL] [Abstract][Full Text] [Related]
46. Platelet--von Willebrand factor interactions in type IIB von Willebrand's disease. Holmberg L; Kristoffersson AC; Lamme S; Nilsson IM; Awidi A; Solum NO Scand J Haematol; 1985 Sep; 35(3):305-14. PubMed ID: 3877338 [TBL] [Abstract][Full Text] [Related]
47. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease. Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759 [TBL] [Abstract][Full Text] [Related]
48. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976 [TBL] [Abstract][Full Text] [Related]
49. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Jenkins PV; Pasi KJ; Perkins SJ Blood; 1998 Mar; 91(6):2032-44. PubMed ID: 9490688 [TBL] [Abstract][Full Text] [Related]
50. Membrane fluidity and platelet aggregation: dibucaine permits ristocetin-induced platelet aggregation with low-molecular-weight von Willebrand multimers. Gjønnaess E; Solum NO; Brosstad F Blood Coagul Fibrinolysis; 1992 Aug; 3(4):395-405. PubMed ID: 1420815 [TBL] [Abstract][Full Text] [Related]
51. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma. Casonato A; De Marco L; Mazzucato M; De Angelis V; De Roia D; Fabris F; Ruggeri ZM; Girolami A Blood; 1989 Nov; 74(6):2028-33. PubMed ID: 2804346 [TBL] [Abstract][Full Text] [Related]
52. Identification of new type 2B von Willebrand disease mutations: Arg543Gln, Arg545Pro and Arg578Leu. Hilbert L; Gaucher C; Abgrall JF; Parquet A; Trzeciak C; Mazurier C Br J Haematol; 1998 Dec; 103(3):877-84. PubMed ID: 9858249 [TBL] [Abstract][Full Text] [Related]
53. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Holmberg L; Berntorp E; Donnér M; Nilsson IM Blood; 1986 Sep; 68(3):668-72. PubMed ID: 3488775 [TBL] [Abstract][Full Text] [Related]
54. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. Holmberg L; Dent JA; Schneppenheim R; Budde U; Ware J; Ruggeri ZM J Clin Invest; 1993 May; 91(5):2169-77. PubMed ID: 8486782 [TBL] [Abstract][Full Text] [Related]
55. Effects of different amino-acid substitutions in the leucine 694-proline 708 segment of recombinant von Willebrand factor. Hilbert L; Gaucher C; Mazurier C Br J Haematol; 1995 Dec; 91(4):983-90. PubMed ID: 8547152 [TBL] [Abstract][Full Text] [Related]
57. Botrocetin- and polybrene-induced platelet aggregation in platelet-type von Willebrand disease. Takahashi H; Nagayama R; Hattori A; Shibata A Am J Hematol; 1985 Feb; 18(2):179-89. PubMed ID: 3871585 [TBL] [Abstract][Full Text] [Related]
58. von Willebrand factor without the A2 domain is resistant to proteolysis. Lankhof H; Damas C; Schiphorst ME; Ijsseldijk MJ; Bracke M; Furlan M; Tsai HM; de Groot PG; Sixma JJ; Vink T Thromb Haemost; 1997 May; 77(5):1008-13. PubMed ID: 9184419 [TBL] [Abstract][Full Text] [Related]
59. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442 [TBL] [Abstract][Full Text] [Related]
60. New variant of type II von Willebrand's disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding history. Baillod P; Gaucher C; Affolter B; Mazurier C; Pflugshaupt R Am J Hematol; 1995 May; 49(1):21-8. PubMed ID: 7741134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]